文献速递前列腺癌

低危前列腺癌管理趋势与实践:SEER-Medicare研究

Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-06-09

该研究利用SEER-Medicare数据库分析2010-2013年诊断为低危前列腺癌的66岁以上男性,发现期待管理(EM)比例从29.4%升至49.0%,但仍有超过50%接受积极治疗。EM患者中仅39%启动主动监测(AS),3年内21.3%转为积极治疗。

要点

  • 低危前列腺癌的期待管理使用率显著上升,从29.4%增至49.0%。
  • EM患者中仅39%启动AS监测,约60%未启动,可能接受观察等待。
  • 诊断后3年内,21.3%的EM患者转为积极治疗。

核心结论

  • 低危前列腺癌的期待管理使用率随时间增加,但超过50%患者仍接受积极治疗。
  • 约60%的EM患者未启动AS监测,即使在预期寿命>10年的患者中也是如此。
  • AS监测与转为积极治疗相关,提示治疗决策可能基于癌症进展。

研究设计与样本

  • 基于SEER-Medicare数据库的回顾性队列研究。
  • 纳入2010-2013年诊断为低危前列腺癌(PSA<10 ng/mL,Gleason≤6,分期≤T2a)的66岁以上男性,随访至少1年。

主要发现

  • EM比例从29.4%上升至49.0%(p<0.01)。
  • 与EM相关的因素包括年龄<77岁、已婚/有伴侣、非西班牙裔、较高邮编收入中位数、较低PSA水平、T1c期及较晚诊断年份。
  • EM队列中39%启动AS监测,相关因素包括年龄<77岁、白人种族、已婚/有伴侣、较高收入中位数及较低PSA水平。
  • 诊断后3年内,21.3%的EM患者转为积极治疗,通常发生在AS监测程序之后。

关键数值与推荐

  • 低危前列腺癌定义:PSA<10 ng/mL,Gleason评分≤6,分期≤T2a。
  • EM定义为诊断后1年内未接受积极治疗。

临床怎么用

  • 临床实践中应更广泛地采用期待管理治疗低危前列腺癌。
  • 对选择EM的患者,应规范启动AS监测(PSA检测和前列腺活检)。
  • 需关注EM患者中未启动AS监测的情况,避免不当的观察等待。

局限性

  • 研究为回顾性设计,可能存在未测量的混杂因素。
  • 使用理赔数据定义治疗和监测,可能存在编码不准确。
  • 研究对象为66岁以上Medicare参保男性,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Expectant management (EM) has been widely recommended for men with low-risk prostate cancers (PCa). We evaluated trends in EM and the sociodemographic and clinical factors associated with EM, initiating a National Comprehensive Cancer Network guideline-concordant active surveillance (AS) monitoring protocol, and switching from EM to active treatment (AT). METHODS: We used the SEER-Medicare database to identify men ages 66+ diagnosed with a low-risk PCa (PSA < 10 ng/mL, Gleason ≤ 6, stage ≤ T2a) in 2010-2013 with ≥1 year of follow-up. We used claims data to capture (1) PCa treatments, including surgical procedures, radiotherapy, and hormone therapy, and (2) AS monitoring procedures, including PSA tests and prostate biopsy. We defined EM as receiving no AT within 1 year of diagnosis. We used multivariable regression techniques to identify factors associated with EM, initiating AS monitoring, and switching to AT. RESULTS: During the study period, EM increased from 29.4% to 49.0%, p < 0.01. Age < 77, being married/partnered, non-Hispanic ethnicity, higher median ZIP code income, lower PSA levels, stage T1c, and more recent year of diagnosis were associated with EM. Nearly 39% of the EM cohort initiated AS monitoring; age <77, White race, being married/partnered, higher median ZIP code income, and lower PSA levels were associated with initiating AS. By three years after diagnosis, 21.3% of the EM cohort had switched to AT, usually after undergoing AS monitoring procedures. DISCUSSION: We found increasing uptake of EM over time, though over 50% still received AT. About 60% of EM patients did not initiate AS monitoring, even among those with life expectancy >10 years, implying that a substantial proportion was being managed by watchful waiting. AS monitoring was associated with switching to AT, suggesting that treatment decisions likely were based on cancer progression.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Hoffman RM, Mott SL, McDowell BD, et al. Trends and practices for managing low-risk prostate cancer: a SEER-Medicare study. Prostate Cancer Prostatic Dis. 2021. PMID: 34108645. doi:10.1038/s41391-021-00393-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。